Minneapolis, MN, March 17, 2017 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical accessory aggregation developing the PURE EP(TM) System, a proprietary belvedere advised to abode an unmet technology allegation for the $4 billion electrophysiology (EP) marketplace, today appear it has active a ten-year cardinal acceding with Mayo Clinic and Mayo Clinic Ventures. This new, broadcast accord with Mayo builds aloft the assignment accomplished beneath the Avant-garde Analytic Analysis Program that was active with Mayo Clinic in March 2016.
BioSig intends to assignment carefully with Drs. Samuel Asirvatham and K. L. Venkatachalam, arch Mayo electrophysiologists, to advance avant-garde ytic appearance and applications for its PURE EP System, as able-bodied as to advantage the company’s amount adequacy in physiologic arresting processing to advance approaching technologies. Mayo is accepted to accord know-how, bookish acreage and ytic abutment to the partnership. The aggregation expects collective apparent filings to appear out of the relationship.
Kenneth L. Londoner, Executive Chairman and Founder commented, “We are admiring to strengthen and augment our accord with Mayo Clinic and Mayo Ventures to abound our addition capabilities and bear above medical technology.”
Greg Cash, President and CEO added, “Our acquaintance alive with Drs. Asirvatham and Venkatachalam has been outstanding and has resulted in three associate advised publications to-date. Adding addition and bookish acreage to the blueprint should accession this accord to a accomplished new level, acceptable consistent in bigger ysis and ysis of circuitous arrhythmias in abounding patients.”
About BioSig Technologies
BioSig Technologies is a medical accessory aggregation developing a proprietary technology belvedere advised to advance the $4 billion electrophysiology (EP) exchange (www.biosigtech.com). Led by a accurate administration aggregation and a veteran, absolute Board of Directors, Minneapolis-based BioSig Technologies is advancing to commercialize its PURE EP(TM) System.
BioSig’s technology has been developed to abode an unmet allegation in a ample and growing market. The PURE EP Arrangement is a atypical cardiac arresting accretion and affectation arrangement which is engineered to abetment electrophysiologists in ytic accommodation authoritative during procedures to yze and amusement patients with aberrant affection ante and rhythms. BioSig’s capital ambition is to bear technology to advance aloft catheter ablation treatments for the accustomed and baleful arrhythmias, Atrial Fibrillation and Ventricular Tachycardia.
Data from the 2016 HRI All-around Opportunities in Medical Accessories & Diagnostics address shows the all-around Electrophysiology (EP) bazaar revenues is accepted to abound about 10% annually, from currently $4 billion to about $6 billion by 2020 with accompanying action advance aing to 10% annually, from 865,000 patients in 2015 to 1,350,000 in 2020. Procedure advance in the United States abandoned is projected at an 11.0% anniversary rate, from 250,000 in 2015 to 422,000 in 2020; accompanied by an 11.7% advance in revenues, from $1.85 billion in 2015 to $3.220 billion in 2020.
BioSig has partnered with Minnetronix on technology development and is alive against FDA 510(k) approval and CE Mark for the PURE EP System. The aggregation has accomplished affidavit of abstraction validation and activated its ancestor at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center, and has performed pre-clinical studies at Mayo Clinic in Minnesota and Mount Sinai Hospital in NY. The aggregation continues to accomplish ysis and development studies in the anatomy of an Avant-garde Analysis Program at Mayo Clinic which began in June 2016. Added celebrated cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute and UH Case Medical Center in Cleveland additionally comedy an important role in the PURE EP technology.
About Mayo Clinic and Mayo Ventures
With added than 32,000 advisers in Roer, Minnesota, Mayo Clinic is the better non-government employer in Minnesota with an estimated bread-and-er appulse above $10 billion. It is additionally a ysis powerhouse, bearing new biologic therapies, medical devices, software and added acid bend account that accept spawned over 100 new companies in the accomplished 15 years through authorization and cardinal deals. Mayo’s $6 billion “Destination Medical Center” is a above amplification activity in Roer, Minnesota that will clean the city’s downtown, add addition 30,000 jobs and should about-face the breadth into a common allurement for accommodating care.
This columnist absolution contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or agnate words. Advanced statements are not guarantees of approaching performance, are based on assertive assumptions and are accountable to assorted accepted and alien risks and uncertainties, abounding of which are above the Company’s control, and cannot be predicted or quantified and consequently, absolute after-effects may alter materially from those bidding or adumbrated by such advanced statements. Such risks and uncertainties include, after limitation, risks and uncertainties associated with (i) our disability to accomplish our artefact candidates on a bartering calibration on our own, or in accord with third parties; (ii) difficulties in accepting costs on commercially reasonable terms; (iii) changes in the admeasurement and attributes of our competition; (iv) accident of one or added key admiral or scientists; and (v) difficulties in accepting authoritative approval to bazaar our artefact candidates.. Added abundant advice about the Aggregation and the accident factors that may affect the ability of advanced attractive statements is set alternating in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Anniversary Address on Anatomy 10-K and its Quarterly Reports on Anatomy 10-Q. Investors and aegis holders are apprenticed to apprehend these abstracts chargeless of allegation on the SEC’s web armpit at http://www.sec.gov. The Aggregation assumes no obligation to about amend or alter its advanced statements as a aftereffect of new information, approaching contest or otherwise.
Mayo Clinic Release Of Information Form Will Be A Thing Of The Past And Here’s Why | Mayo Clinic Release Of Information Form – mayo clinic release of information form
| Delightful to be able to the blog, on this time period I am going to show you with regards to mayo clinic release of information form
. And today, this is actually the very first photograph: